Uncategorized

PTA Member Nutromics publishes important study in Nature Biotechnology    PTA member and Australian Innovator Nutromics are pioneers in the wearable and skin patch diagnostic technology space.   A pilot study of their electrochemical aptamer-based patch for continuous drug monitoring was recently published in Nature Biotechnology. See below for details.  Nutromics are based in Melbourne and have been a members of PTA for […]

Importance of diagnostic testing in the management of Antimicrobial Resistance (AMR).  Feb 23 2026  Australia’s CDC has just published the Aura Report, the sixth Australian report on antimicrobial use and resistance in human health.  Here is a link to the full report.  AURA REPORT – Sixth Australian report on antimicrobial use and resistance in human health  In

Same root cause, different impact – HTA PBAC and MSAC have passed their use by date  10th February 2026  This week the ABC reported on the lack of PBS funding for some commonly used medicines. See the link below for the full article.   Essentially the issue boils down to the same root cause as we find for

  Dean Whiting warns Australia has a narrow window to implement systemic change before healthcare becomes unsustainable  January 2025 – Pathology Technology Australia (PTA) CEO Dean Whiting has delivered a sobering assessment of the healthcare sector’s trajectory, warning that critical policy initiatives have stalled despite the government’s return to office earlier this year.  Speaking with Health

Joint Statement on the Commencement of Genomics Australia Pathology Technology Australia and the Industry Genomics Network Alliance (InGeNA) warmly welcome the formal establishment of Genomics Australia as a national body under the Department of Health and Aged Care from 1 July. We commend the calibre of the Genomics Australia leadership team, which brings together deep

The Missing Piece – Why are we not funding these tests to reduce pregnancy risk? “If I had access to a test that could predict my risk for pre-eclampsia I could have prevented a life-threatening situation for me and for my baby” – Sarah, pre-eclampsia survivor. Sarah spent a week in hospital with dangerously high

Significant delays in diagnostic funding means patients are missing out The path to Medicare funding for new diagnostic technology is a notoriously challenging one, and a recent publication has now quantified the significant delay in Australia’s health technology assessment pathways. The poster, presented at ISPOR—The Professional Society for Health Economics and Outcomes Research, a collaborative

The Missing Piece – ovarian cancer It took over 2 years for access to testing that identified suitable treatment for newly diagnosed ovarian cancer patients, during which time 88 LIVES were lost and an estimated $319.1 MILLION in benefits were foregone. A universal provision offering fully funded genetic testing for all cancers would avoid delays and open up

2025-26 Labor Government Budget proposals as they relate to Health:  In a rare 4th budget announcement within a single term of government, the Labor Treasurer, Hon Jim Chalmers, appealed for stability and the chance for a second term for Labor to guide Australians through “uncertain times”. The budget has a strong focus on cost-of-living pressures

  The peak body representing private pathology in Australia, Australian Pathology, launched a widespread campaign that has been running since 2024 – “Keep Pathology Bulk Billed”. This multi-channel initiative can be seen on TV commercials, Mainstream news and media articles, social media, and billboards. Aimed at raising awareness of the long-term stagnation in Medicare rebates